Rethinking Long-Term Dry Eye Treatment
Dry eye disease frequently requires ongoing treatment, often involving repeated self-administration of topical medications.
For pharmaceutical companies, this creates an opportunity to explore a differentiated treatment model: sustained local ocular therapy designed to reduce reliance on frequent drug administration.
BM Pharma is investigating an innovative long-acting ocular delivery concept with the goal of enabling a more convenient, clinician-managed treatment approach.
Multi-month delivery is a development objective, subject to experimental and clinical validation.
The Product Opportunity
Our program explores an alternative to conventional eye-drop delivery through controlled and sustained local drug administration.
The development strategy focuses on three potential sources of product value:
1. Treatment Convenience
Explore whether sustained delivery could reduce the burden of repeated administration.
2. Product Differentiation
Investigate a differentiated ophthalmic product concept with a potentially distinct clinical and commercial profile.
3. Milestone-Driven Development
Advance the program through measurable technical and preclinical milestones, allowing partners to evaluate investment decisions as evidence develops.
Building Evidence That Matters
The feasibility program will focus on four critical questions:
Delivery-System Performance
Can the system maintain reliable local retention and predictable drug release?
Ocular Exposure and Tolerability
Can sustained delivery achieve relevant local exposure with acceptable ocular compatibility?
Drug-Specific Therapeutic Contribution
Can the active drug demonstrate meaningful effects beyond those attributable to the delivery system alone?
Clinical and Commercial Translation
Can the approach offer a practical treatment pathway with a compelling benefit–risk and treatment-burden profile?
Current Development Stage
Early-Stage R&D | Feasibility Validation
The program has a defined development concept and a proposed technical evaluation framework.
Key delivery-performance, pharmacokinetic, safety and therapeutic questions remain subject to experimental validation.
The next development phase is intended to generate decision-grade evidence to support candidate selection and further preclinical development.
Partnering Opportunity
BM Pharma invites discussions with ophthalmology-focused pharmaceutical companies interested in differentiated dry eye product opportunities.
Potential collaboration structures include funded feasibility evaluation, milestone-driven co-development, and technology licensing and regional development rights, subject to agreement.
Partners may participate early in shaping the development strategy, with subsequent investment decisions linked to predefined scientific and technical milestones.
Explore a Partnership
Detailed formulation, intellectual property and supporting technical information will be made available through an appropriate confidential partnering process.
This is an investigational development program. Target delivery duration, clinical efficacy, safety, and reduced dosing frequency have not been established.
